Table 1.

Model Parameters and references

Parameter	Estimate	Reference
PWID population size in Athens (95% CI)	8300 (6392–10985)	(34)
Anti-HCV prevalence among PWID (95% CI)	80% (77.5%, 82.5%)	(34)
Proportion acutely infected spontaneously clearing infection	20%	(37)
Duration of injecting carrier among PWID in Athens	12 years	(31)
Overall PWID mortality	2%	(50–52)
Proportion of PWID at high risk (η)*	23%	(31)
Proportion participating in harm reduction programmes (OST or high coverage HCNSP) (β)	44%	(32)
Relative risk for HCV infection for high risk PWID (Π)	2.3	(31)
Relative risk for HCV infection while in a harm reduction programme (Z)	0.41	(7)
Duration in the high risk group (12/κ)	12 months	(32)
Duration of DAA therapy (52/T)	12 weeks	(40)
Proportion achieving SVR IFN-free DAAs	90% until 2017 95% until 2030	(41–43)

^*Defined as proportion of PWID experiencing unstable housing